Management of pituitary gonadal function via gonadotrophin releasing hormone (GnRH) antagonists, including ovulation induction by co-administration of either gonadotrophins or pulsatile GnRH.
GnRH agonists are now familiar clinical agents and are often the drugs of choice for suppression of the pituitary gonadal axis as part of various clinical indications. GnRH antagonists, which are likely to become clinically available soon, offer several advantages over the currently available GnRH agonists for many applications including ovulation induction. Here, we review the results from a series of pre-clinical studies designed to evaluate the potential clinical utility of this new class of compounds for ovulation induction protocols.
Gordon
K
K
Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Department of Obstetrics and Gynecology, Norfolk 23507.
Irianni
F
F
Hodgen
G D
GD
D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006062:Gonadotropins / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000503:physiopathology; D010053:Ovary / Q000503:physiopathology*; D010062:Ovulation Induction; D010507:Periodicity; D010902:Pituitary Gland / Q000503:physiopathology*
D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone